Pentraxin 3 and complement cascade activation in the failure of arteriovenous fistula

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 241-247

  Castellano, Giuseppe ^a   Di Vittorio, Angela ^a   Dalfino, Giuseppe ^a   Loverre, Antonia ^a   Marrone, Daniela ^a   Simone, Simona ^a   Schena, Francesco Paolo ^a   Pertosa, Giovanni ^a   Grandaliano, Giuseppe ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Arterovenous fistula; Complement; Emodialysis; Endothelial cells; Pentraxin 3

Indexed keywords

CELL MARKER; COMPLEMENT MEMBRANE ATTACK COMPLEX; MESSENGER RNA; PENTRAXIN 3;

ADULT; AGED; ARTERIOVENOUS FISTULA STENOSIS; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONFOCAL LASER MICROSCOPY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INNATE IMMUNITY; KIDNEY FAILURE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STENOSIS; VASCULAR ACCESS; VEIN WALL;

ADULT; AGED; ARTERIOVENOUS ANASTOMOSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; CONSTRICTION, PATHOLOGIC; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; RENAL DIALYSIS; RNA, MESSENGER; SERUM AMYLOID P-COMPONENT; TREATMENT FAILURE;

EID: 77249169706     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.044     Document Type: Article

References (31)

1. Binder C.J., Chang M.K., Shaw P.X., et al. Innate and acquired immunity in atherogenesis. Nat Med 8 (2002) 1218-1226
2. Glass C.K., and Witztum J.L. Atherosclerosis. The road ahead. Cell 104 (2001) 503-516
3. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 1876-1890
4. Garlanda C., Bottazzi B., Bastone A., and Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23 (2005) 337-366
5. Peri G., Introna M., Corradi D., et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102 (2000) 636-641
6. Mantovani A., Garlanda C., Bottazzi B., et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 45 (2006) 326-330
7. Rolph M.S., Zimmer S., Bottazzi B., Garlanda C., Mantovani A., and Hansson G.K. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22 (2002) e10-e14
8. van Rossum A.P., Pas H.H., Fazzini F., et al. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 54 (2006) 986-991
9. Baruah P., Dumitriu I.E., Peri G., et al. The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 80 (2006) 87-95
10. Nauta A.J., Bottazzi B., Mantovani A., et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 33 (2003) 465-473
11. Oksjoki R., Kovanen P.T., Meri S., and Pentikainen M.O. Function and regulation of the complement system in cardiovascular diseases. Front Biosci 12 (2007) 4696-4708
12. Fosbrink M., Niculescu F., Rus V., Shin M.L., and Rus H. C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 281 (2006) 19009-19018
13. Feldman H.I., Kobrin S., and Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 7 (1996) 523-535
14. Roy-Chaudhury P., Sukhatme V.P., and Cheung A.K. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 17 (2006) 1112-1127
15. Roy-Chaudhury P., Arend L., Zhang J., et al. Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis 50 (2007) 782-790
16. Wang Y., Krishnamoorthy M., Banerjee R., et al. Venous stenosis in a pig arteriovenous fistula model-anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant 23 (2008) 525-533
17. Castellano G., Woltman A.M., Nauta A.J., et al. Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood 103 (2004) 3813-3820
18. Marrone D., Pertosa G., Simone S., et al. Local activation of interleukin 6 signaling is associated with arteriovenous fistula stenosis in hemodialysis patients. Am J Kidney Dis 49 (2007) 664-673
19. Hansson G.K., and Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6 (2006) 508-519
20. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
21. Presta M., Camozzi M., Salvatori G., and Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 11 (2007) 723-738
22. Mantovani A., Garlanda C., Doni A., and Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long Pentraxin PTX3. J Clin Immunol 28 (2008) 1-13
23. Boehme M., Kaehne F., Kuehne A., et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant 22 (2007) 2224-2229
24. Kotooka N., Inoue T., Fujimatsu D., et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 197 1 (2007) 368-374
25. Napoleone E., di Santo A., Peri G., et al. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol 76 (2004) 203-209
26. Schepers A., de Vries M.R., van Leuven C.J., et al. Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. Circulation 114 (2006) 2831-2838
27. Halperin J.A., Taratuska A., and Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 91 (1993) 1974-1978
28. Benzaquen L.R., Nicholson-Weller A., and Halperin J.A. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179 (1994) 985-992
29. Niculescu F., Badea T., and Rus H. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 142 (1999) 47-56
30. Torzewski J., Torzewski M., Bowyer D.E., et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18 (1998) 1386-1392
31. Viedt C., Hansch G.M., Brandes R.P., Kubler W., and Kreuzer J. The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1. FASEB J 14 (2000) 2370-2372